PMID- 22007490
OWN - NLM
STAT- MEDLINE
DCOM- 20120503
LR  - 20111019
IS  - 1672-173X (Print)
IS  - 1672-173X (Linking)
VI  - 42
IP  - 5
DP  - 2011 Sep
TI  - [Application value of combining brain natriuretic peptide, creatine phosphokinase 
      and echocardiogram in the evaluation of polymyositis-related chronic heart 
      failure].
PG  - 646-8, 660
AB  - OBJECTIVE: To explore the application value of combining brain natriuretic 
      peptide (BNP), creatine phosphokinase (CPK) and echocardiogram in the evaluation 
      of olymyositis-related chronic heart failure (CHF). METHODS: Twenty-five 
      polymyositis (PM) patients with CHF (NYHA grade II-IV) were evaluated with New 
      York Heart Association (NYHA) criteria for heart failure. Serum concentration of 
      BNP and CPK were detected by the methods of enzyme linked immunosorbent assay and 
      automatic biochemistry analyzer respectively. Echocardiogram was used to 
      calculate left ventricular ejection fraction (LVEF). Thirty PM patients without 
      CHF were also investiaged as control. RESULTS: Serum concentrations of BNP, CPK 
      in PM with CHF were significantly higher than those in PM without CHF (P < 0.01). 
      Compared with the level before intervention, BNP concentration in PM with CHF 
      decreased sharply after 14 days therapy (P < 0.05), while the decrease of BNP 
      concentration was not statistically significant (P > 0.05) in PM without CHF 
      after the therapy. The concentration of CPK was much lower in PM patients either 
      with or without CHF after therapy (P < 0.05). Among each group of NYHA grade 
      II-IV, there was statistical significant difference of BNP concentration (P < 
      0.05). Statistical significant difference of CPK concentration was only found 
      between grade II and grade IV patients. The difference of BNP was not statistical 
      significant between PM patients without CHF but CPK > 2 000 IU/L and PM with 
      grade II CHF. BNP concentration was significantly different between PM patients 
      with LVEF > 40% and those with LVEF < or = 40% (P < 0.05). CONCLUSION: BNP is a 
      good marker for PM with CHF and correlates well with LVEF and NYHA grades. In 
      addition, it plays a suggestive role in diagnosing CHF in PM with CPK > 2 000 
      IU/L.
FAU - Yin, Geng
AU  - Yin G
AD  - Department of Rheumatology and Immunology, West China Hospital, Sichuan 
      University, Chengdu 610041, China.
FAU - Mao, Lei
AU  - Mao L
FAU - Cen, Xiao-Min
AU  - Cen XM
FAU - Yang, Min
AU  - Yang M
FAU - Xie, Qi-Bing
AU  - Xie QB
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Sichuan Da Xue Xue Bao Yi Xue Ban
JT  - Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical 
      science edition
JID - 101162609
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - EC 2.7.3.2 (Creatine Kinase)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Creatine Kinase/*blood
MH  - *Echocardiography, Doppler, Color
MH  - Female
MH  - Heart Failure/blood/*diagnosis/etiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/*blood
MH  - Polymyositis/blood/*complications/physiopathology
MH  - Young Adult
EDAT- 2011/10/20 06:00
MHDA- 2012/05/04 06:00
CRDT- 2011/10/20 06:00
PHST- 2011/10/20 06:00 [entrez]
PHST- 2011/10/20 06:00 [pubmed]
PHST- 2012/05/04 06:00 [medline]
PST - ppublish
SO  - Sichuan Da Xue Xue Bao Yi Xue Ban. 2011 Sep;42(5):646-8, 660.